Breakthrough in cell-based assay development
29 April 2008
US company MaxCyte has introduced the ITF Inline Transfection System,
a validated platform for preparative transfection, based on unique flow
electroporation technology. The system enables rapid and efficient
transfection of any kind of cell or cell line with any molecule
(plasmids, proteins, protein complexes, drugs, mRNA, siRNA), at scales
ranging from micro-litres to litre volumes.
MaxCyte's ITF Inline Transfection System enables transient
transfection of cell lines as well as primary cells, and is now
available for drug discovery and screening applications. The sterile,
closed system provides consistency, scalability, and loading efficiency
while avoiding the inherent drawbacks of alternative methods.
Many cell based assays and research projects are based on recombinant
cell lines. Optimizing such cell lines so they express a desired set of
properties and are compatible with a particular screening platform takes
considerable time and expense. Because of its ease and speed, transient
transfection is increasingly used to replace cloning and recombinant
work in a wide range of applications (eg ion channel-based drug or GPCR
The MaxCyte ITF Inline Transfection system replaces current
preparative transfection technologies which depend on expensive and
complicated virus constructs, lipid-based transfection agents, or small
scale electroporation devices.